🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

114 results for “CG” Clear

  1. Peanut food challenge, oral paste “high dose” - 133.3 mg/g peanut proteins, Peanut food challenge, oral paste “placebo” - Placebo formulation, Soluprick Positive control, 10 mg/ml, Solution for skin-prick test, Viaskin Peanut, Soluprick Negative control, Solution for skin prick test, ALK 762 Jordnød, Opløsning til priktest (Soluprick), Nøddeallergen, The DBV712 Placebo Patch is the same system as DBV712 250 mcg Patch but without peanut proteins, Peanut food challenge, oral paste “low dose” - 6.6 mg/g peanut

    DBV Technologies

    Peanut allergy

    phase 3 small molecule active

    1 trial

  2. Placebo, CEMIPLIMAB

    Cancer Prevention Pharma (Ireland) Limited

    Non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  3. Salbutamol Aldo-Unión 100 microgramos/dosis suspensión para inhalación en envase a presión, Inhalation powder with lactose monohydrate and magnesium stearate, BREO ELLIPTA, Fluticasone furoate and Vilanterol inhalation powder 100 mcg/25 mcg

    Sandoz Pharmaceuticals d.d.

    Asthma

    phase 3 small molecule active

    1 trial

  4. Sufentanil 30 MCG Sublingual Tablet

    United Therapeutics Europe Ltd

    Traumatic Injury

    phase 3 small molecule completed

    1 trial

  5. Tice® BCG (for intravesical use) BCG LIVE strain of the BCG (Merck) vaccine

    United Therapeutics Europe Ltd

    COVID-19

    phase 3 small molecule terminated

    1 trial

  6. 6QC-ICG, Placebo for 6QC-ICG

    Disc Medicine

    Breast cancer

    phase 2 small molecule active

    1 trial

  7. A Phase 1/2 Study of EG-70 as an Intravesical Administration to Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) and High-Risk NMIBC Patients who are BCG Naïve or Received Incomplete BCG Treatment

    enGene Therapeutics

    Non-muscle invasive bladder cancer (NMIBC)

    phase 2 other active

    1 trial

  8. A Phase 2, Multiple Ascending Dose, Open-label, Proof-of-concept Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Activity of HM15136 Treatment for 8 Weeks in Subjects Aged ≥2 Years With Congenital Hyperinsulinism (CHI) (ACHIEVE)

    Pharm Research Associates (UK) Limited

    Congenital Hyperinsulinism (CHI)

    phase 2 other active

    1 trial

  9. ALX1-11 50 mcg

    Takeda Pharmaceuticals International AG

    Osteoporosis

    phase 2 small molecule completed

    1 trial

  10. AXATILIMAB

    Syndax Pharmaceuticals Inc

    Chronic graft versus host disease (cGVHD)

    phase 2 small molecule active

    1 trial

  11. Albuterol DPI 25 mcg/inh

    Amphastar France Pharmaceuticals

    Asthma

    phase 2 small molecule completed

    1 trial

  12. Arm T Epinephrine Inhalation Aerosol HFA, 125 mcg, 1 inhalation

    Amphastar France Pharmaceuticals

    Asthma

    phase 2 small molecule terminated

    1 trial

  13. BCG-MEDAC, poudre et solvant pour suspension intravésicale, PD1IL2v iMAb

    Roche Registration Limited

    BCG-Unresponsive High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC)

    phase 2 small molecule active

    1 trial

  14. CAPECITABINE, CAPECITABINE, PEMBROLIZUMAB

    Cancer Prevention Pharma (Ireland) Limited

    Triple Negative Breast Cancer with residual disease after neoadjuvant chemo-immunotherapy.

    phase 2 small molecule active

    1 trial

  15. CG0070

    CG Oncology

    Non Muscle Invasive Bladder Cancer

    phase 2 mab completed

    1 trial

  16. CG0070

    CG Oncology

    Bladder Cancer

    phase 2 mab completed

    1 trial

  17. CGT4859

    Cogent Biosciences

    Intrahepatic Cholangiocarcinoma (Icc)

    phase 2 small molecule active

    1 trial

  18. CGT9486

    Cogent Biosciences

    Gastrointestinal Stromal Tumors

    phase 2 small molecule completed

    1 trial

  19. CGT9486, CGT9486

    Cogent Biosciences

    Advanced Systemic Mastocytosis

    phase 2 small molecule active

    1 trial

  20. Cretostimogene Grenadenorepvec

    CG Oncology

    High-Risk Non-Muscle-Invasive Bladder Cancer

    phase 2 small molecule active

    1 trial

  21. Drug will be recommended based on IHC/Fish, CGH and Pan-XenoBank

    BRIGHT MINDS BIOSCIENCES INC.

    Previously Treated Metastatic Pancreatic Cancer

    phase 2 small molecule completed

    1 trial

  22. E004 (epinephrine inhalation aerosol), 90 mcg/actuation

    Amphastar France Pharmaceuticals

    Asthma

    phase 2 small molecule terminated

    1 trial

  23. EXEMESTANE, ANASTROZOLE, LETROZOLE

    Cancer Prevention Pharma (Ireland) Limited

    Post-menopausal women with localized luminal A breast cancer and considered at low risk of metastatic relapse

    phase 2 small molecule active

    1 trial

  24. EXEMESTANE, ANASTROZOLE, LETROZOLE, TAMOXIFEN

    Cancer Prevention Pharma (Ireland) Limited

    Postmenopausal patients with small (pT1a-b pN0) hormone receptor positive (HR⁺) and HER2 negative (HER2⁻) early breast cancer with a Luminal A phenotype and at low risk of recurrence.

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources